The way diabetic patients receive insulin and manage their disease could go through some major changes in the next few years, and that is turning the field into a very active marketplace that medical professionals as well as investors are watching closely. The major shift starts with insulin injections, which will remain a key component of managing blood sugar levels, but new delivery systems are offering a more appealing alternative to the pain, inconvenience, and stigma of using syringes, and manufacturers are pursuing the large type 2 (T2) diabetic population for these new systems.
The benchmark of progress in diabetes treatments is usually measured at the American Diabetes Association (ADA) annual industry conference, and...